Harrow Q3 Earnings Call Highlights
Harrow reported Q3 revenue of $99.3M, with VEVYE contributing $39.7M (up 35% sequentially). IHEEZO and TRIESENCE unit demand rose 21% and 37% sequentially, respectively. The QUELL study missed its primary endpoint but showed lower pain scores for IHEEZO. Harrow plans to submit a new drug application for G-MELT and is in discussions regarding licensing agreements.
How this was made
The 30-second read
Why it matters
The earnings release provides fresh data on product performance and pipeline risk, informing short‑term trading decisions.
Market read
Earnings and trial data are material for HROW shareholders and biotech traders; limited spillover to broader market.
What to watch
Potential upside from the national plan covering 10 million lives and upcoming FDA review timeline.
Background
Harrow (NASDAQ:HROW) reported Q3 results, highlighted growth in VEVYE and IHEEZO sales, and disclosed a Phase IV trial that failed to meet its primary endpoint.
Ticker impact
Q3 earnings call disclosed revenue breakdown, unit demand growth, and a failed Phase IV QUELL trial for IHEEZO.
potential downside as investors price in trial uncertainty and lack of near‑term study plans.
Revenue growth is solid, yet the non‑inferiority failure for IHEEZO introduces risk to the pipeline, likely prompting a modest sell‑off.
Market effects
Eye‑care biotech sector may see heightened scrutiny of trial data.
U.S. biotech investors may adjust exposure to ophthalmic drug developers.
Limited to niche ophthalmology market; no broad macro effect.
Counterpoint
Despite the trial miss, strong revenue growth and upcoming G‑MELT NDA filing could support upside.
Key entities
- companyHarrow
NASDAQ‑listed ophthalmic pharmaceutical company.
- productVEVYE
Dry‑eye treatment generating $39.7 M in Q3.
- productIHEEZO
Ophthalmic anesthetic gel with trial miss.
